Targeting nicotinic receptor antagonists as novel pharmacotherapies for tobacco dependence and relapse.
作者信息
Dwoskin Linda P, Bardo Michael T
机构信息
University of Kentucky National Cooperative Drug Discovery Group, Lexington, KY, USA.
出版信息
Neuropsychopharmacology. 2009 Jan;34(1):244-6. doi: 10.1038/npp.2008.157.
Abstract
摘要
相似文献
1
Targeting nicotinic receptor antagonists as novel pharmacotherapies for tobacco dependence and relapse.
Neuropsychopharmacology. 2009 Jan;34(1):244-6. doi: 10.1038/npp.2008.157.
2
Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence.
Nebr Symp Motiv. 2009;55:31-63. doi: 10.1007/978-0-387-78748-0_4.
3
Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD).
Biochem Pharmacol. 2007 Oct 15;74(8):1271-82. doi: 10.1016/j.bcp.2007.07.021. Epub 2007 Jul 21.
4
bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse.
Br J Pharmacol. 2011 May;163(2):346-57. doi: 10.1111/j.1476-5381.2011.01220.x.
5
Nicotinic receptor antagonists as treatments for nicotine abuse.
Adv Pharmacol. 2014;69:513-51. doi: 10.1016/B978-0-12-420118-7.00013-5.
6
Nicotinic receptor-based therapeutics and candidates for smoking cessation.
Biochem Pharmacol. 2009 Oct 1;78(7):732-43. doi: 10.1016/j.bcp.2009.06.002. Epub 2009 Jun 10.
7
More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder.
Pharmacol Rev. 2020 Apr;72(2):527-557. doi: 10.1124/pr.119.018028.
8
[New perspectives in the treatment of nicotine dependence].
Pneumologia. 2006 Jan-Mar;55(1):36-9.
9
[Behavioral mechanisms of nicotine dependence: a search for new drugs].
Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(7):73-81.
10
Pharmacotherapy for tobacco dependence.
Handb Exp Pharmacol. 2009(192):487-510. doi: 10.1007/978-3-540-69248-5_17.
引用本文的文献
1
The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.
Psychopharmacology (Berl). 2018 Sep;235(9):2479-2505. doi: 10.1007/s00213-018-4921-9. Epub 2018 Jul 7.
2
Nicotinic receptor antagonists as treatments for nicotine abuse.
Adv Pharmacol. 2014;69:513-51. doi: 10.1016/B978-0-12-420118-7.00013-5.
3
Potential therapeutic uses of mecamylamine and its stereoisomers.
Pharmacol Biochem Behav. 2013 Jul;108:28-43. doi: 10.1016/j.pbb.2013.04.005. Epub 2013 Apr 18.
4
Nicotine as a potential neuroprotective agent for Parkinson's disease.
Mov Disord. 2012 Jul;27(8):947-57. doi: 10.1002/mds.25028. Epub 2012 Jun 12.
5
Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum.
J Pharmacol Exp Ther. 2012 Aug;342(2):327-34. doi: 10.1124/jpet.112.194852. Epub 2012 May 1.
6
α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.
Pharmacol Rev. 2011 Dec;63(4):938-66. doi: 10.1124/pr.110.003269.
7
Indolizidine (-)-235B' and related structural analogs: discovery of nicotinic receptor antagonists that inhibit nicotine-evoked [3H]dopamine release.
Eur J Pharmacol. 2011 May 11;658(2-3):132-9. doi: 10.1016/j.ejphar.2011.02.018. Epub 2011 Mar 1.
8
Structure and activity of alpha-conotoxin PeIA at nicotinic acetylcholine receptor subtypes and GABA(B) receptor-coupled N-type calcium channels.
J Biol Chem. 2011 Mar 25;286(12):10233-7. doi: 10.1074/jbc.M110.196170. Epub 2011 Jan 20.
9
bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse.
Br J Pharmacol. 2011 May;163(2):346-57. doi: 10.1111/j.1476-5381.2011.01220.x.
10
Bis-azaaromatic quaternary ammonium salts as ligands for the blood-brain barrier choline transporter.
Bioorg Med Chem Lett. 2010 Jun 1;20(11):3208-10. doi: 10.1016/j.bmcl.2010.04.098. Epub 2010 Apr 24.
本文引用的文献
1
Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence.
Nebr Symp Motiv. 2009;55:31-63. doi: 10.1007/978-0-387-78748-0_4.
2
Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat.
Drug Metab Dispos. 2008 Oct;36(10):2024-9. doi: 10.1124/dmd.108.020354. Epub 2008 Jul 10.
3
N,N'-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-evoked dopamine release and hyperactivity.
J Pharmacol Exp Ther. 2008 Aug;326(2):563-76. doi: 10.1124/jpet.108.136630. Epub 2008 May 6.
4
Targeted in vivo expression of nicotinic acetylcholine receptors in mouse brain using lentiviral expression vectors.
J Mol Neurosci. 2006;30(1-2):105-6. doi: 10.1385/jmn:30:1:105.
5
The effects of a novel nicotinic receptor antagonist N,N-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) on acute and repeated nicotine-induced increases in extracellular dopamine in rat nucleus accumbens.
Neuropharmacology. 2007 Mar;52(3):755-63. doi: 10.1016/j.neuropharm.2006.09.012. Epub 2006 Nov 9.
6
Effect of a novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide, on nicotine self-administration and hyperactivity in rats.
Psychopharmacology (Berl). 2006 Mar;184(3-4):426-34. doi: 10.1007/s00213-005-0163-8. Epub 2005 Oct 12.
7
Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents.
Bioorg Med Chem Lett. 2004 Apr 19;14(8):1863-7. doi: 10.1016/j.bmcl.2003.10.073.
Zotero 插件